
Pfizer Inc. said during its quarterly earnings call that it will file by the end of May for full Food and Drug Administration approval for its COVID-19 vaccine. More than 131 million doses of the Pfizer vaccine have been administered in the U.S. since it was authorized for emergency use in December.